New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
10:56 EDTMDXGMiMedx says EpiFix addded as covered product in Jurisdiction H
MiMedx Group announced that the Medicare Administrative Contractor responsible for Jurisdiction H, which has approximately five million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas, has revised its Local Coverage Determination, LCD, for bioengineered skin substitutes in the hospital outpatient and physician office settings to include EpiFix. The revision to the LCD, entitled Bioengineered Skin Substitutes, names MiMedx's wound care allograft, EpiFix, as eligible for Medicare coverage when medically necessary and reasonable, subject to the coverage indications and limitations set forth in the LCD. The revision was published on July 10, effective for dates of service on or after June 16. Parker H. "Pete" Petit, Chairman and CEO, said, "As we discussed in our shareholder call on April 25, the contractor for Jurisdiction H previously had issued a draft consolidated LCD under which all skin substitutes with a Q-code were eligible for coverage if the case met the medically necessary and reasonable threshold. This LCD was to go into effect on March 27. On the effective date, the draft LCD was rescinded, and the contractor reverted to the previous LCD. The previous Jurisdiction H LCD covered only a few named skin substitutes and did not include coverage for EpiFix. In the update issued on July 10, the contractor has added EpiFix as a covered product. EpiFix was the only product added in that update. We are very pleased that EpiFix has been included in the revised LCD for this Medicare jurisdiction."
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
09:49 EDTMDXGMiMedx says MTF issued 'second inaccurate' press release
Subscribe for More Information
September 1, 2015
14:35 EDTMDXGMTF 'stands by all statements' made in August 26 press release about PTAB ruling
Subscribe for More Information
August 27, 2015
10:26 EDTMDXGMiMedx says 'inaccuracies' contained in MTF press release on PTAB rulings
Subscribe for More Information
August 26, 2015
09:43 EDTMDXGMiMedx announces publication of study on allografts to regulate diabetic cells
Subscribe for More Information
August 24, 2015
08:56 EDTMDXGMiMedx patent win strengthens IP position, says Brean Capital
Brean Capital noted MiMedx won two Patent Trial and Appeal Board rulings which are involved in the configuration process of two of MiMedx's core products. The firm said the rulings are important wins for the company and strengthens its intellectual properties position. Brean Capital reiterated its Buy rating and $16 price target on MiMedx shares.
August 21, 2015
08:32 EDTMDXGMiMedx patent infringement lawsuits receive rulings from trial and review board
MiMedx announced the Patent Trial and Appeal Board has ruled in favor of the Company's primary EpiFix and AmnioFix patents. In April 2014, MiMedx filed patent infringement lawsuits in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc., Medline Industries, Inc. and Musculoskeletal Transplant Foundation, Inc. for permanent injunctive relief and unspecified damages. In May 2014, the Company also filed a separate action against Transplant Technology, Inc. d/b/a Bone Bank Allograft and Texas Human Biologics Ltd. for patent infringement. In both suits, MiMedx asserted that these organizations infringed and continue to infringe at least six MiMedx patents. As part of their defense strategy, two of the four defendants submitted certain of the MiMedx patents to the inter partes review process, which means they are asking the PTAB to review the subject matter covered by the MiMedx patents and decide whether it was proper for the patents to have been granted in the first place. In general, the inter partes review process works as follows: If the PTAB rejects the request for inter partes review, it essentially means that the PTAB found no basis to challenge the patent on obvious or anticipation grounds. If the PTAB grants inter partes review, it means that the PTAB has found that it is worth reviewing the patent, but by no means is it an indication in and of itself that there is something wrong with the subject patent. MiMedx received two recent rulings from the PTAB. One PTAB ruling was made in regard the inter partes review request related to the MiMedx primary EpiFix patent and the other recent PTAB decision was for the inter partes review request related to the MiMedx AmnioFix patent. In both rulings, the PTAB found no basis to challenge these patents and fully rejected the request for review on these patents.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use